Literature DB >> 20108129

Triad of trichomegaly, alopecia and male-pattern hair growth during treatment with erlotinib in non-small-cell lung cancer.

P Forde1, C Murphy, C O'Sullivan, D Carney.   

Abstract

INTRODUCTION: Description of the cutaneous side effects of erlotinib. MATERIALS: Report with images of a single case.
METHODS: Case report and review of the literature.
CONCLUSION: Erlotinib is associated with significant cutaneous toxicity which should be recognised and managed appropriately.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20108129     DOI: 10.1007/s11845-009-0458-6

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  7 in total

1.  The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome.

Authors:  M E Lacouture; S E Lai
Journal:  Br J Dermatol       Date:  2006-10       Impact factor: 9.302

2.  Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.

Authors:  Judith Elizabeth Carser; Yvonne Jane Summers
Journal:  J Thorac Oncol       Date:  2006-11       Impact factor: 15.609

3.  Erlotinib-associated alopecia in a lung cancer patient.

Authors:  Daniel B Costa; Susumu Kobayashi; Susan T Schumer
Journal:  J Thorac Oncol       Date:  2007-12       Impact factor: 15.609

4.  Images in clinical medicine. Erlotinib-induced hair alterations.

Authors:  Peter Arne Gerber; Bernhard Homey
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

5.  Erlotinib in previously treated non-small-cell lung cancer.

Authors:  Frances A Shepherd; José Rodrigues Pereira; Tudor Ciuleanu; Eng Huat Tan; Vera Hirsh; Sumitra Thongprasert; Daniel Campos; Savitree Maoleekoonpiroj; Michael Smylie; Renato Martins; Maximiliano van Kooten; Mircea Dediu; Brian Findlay; Dongsheng Tu; Dianne Johnston; Andrea Bezjak; Gary Clark; Pedro Santabárbara; Lesley Seymour
Journal:  N Engl J Med       Date:  2005-07-14       Impact factor: 91.245

6.  Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.

Authors:  S Segaert; E Van Cutsem
Journal:  Ann Oncol       Date:  2005-07-12       Impact factor: 32.976

Review 7.  Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

Authors:  Román Peréz-Soler; Leonard Saltz
Journal:  J Clin Oncol       Date:  2005-08-01       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.